We are pleased to announce a significant milestone in the development of European Heart Journal—Cardiovascular Pharmacotherapy (EHJ-CVP): the Journal's transition to an open access publication model. Since the European Society of Cardiology (ESC) and the ESC Working Group on Cardiovascular Pharmacotherapy launched EHJ-CVP in 2015, its editors, reviewers, and authors have worked together to bring the latest developments in clinical cardiovascular pharmacotherapy to clinicians, physicians, researchers, and policy makers worldwide. Moving to fully open access publishing will help us further this mission.
Open access publishing benefits EHJ-CVP because the field of cardiovascular pharmacotherapy stands at the forefront of medical innovation. It is a field wherein immediate access to the latest research can have life-saving implications. Open access publishing helps drive scientific advancement, reducing barriers to knowledge and promoting an environment within which discoveries are shared freely. This model helps ensure that critical insights into drug interactions, therapeutic strategies, and emerging treatments reach clinicians and researchers without delay, thereby accelerating scientific progress and the introduction of groundbreaking therapies.
When this change goes into effect in January 2025 (please note that all manuscripts submitted to EHJ-CVP after 3 September 2024 will publish under an open access license if accepted) the Journal will join ESC's other fully open access titles EP Europace, European Heart Journal—Case Reports, European Heart Journal—Digital Health, European Heart Journal Open, and European Heart Journal—Imaging Methods and Practice.
We invite you to join us in this exciting new chapter, as we continue to serve the cardiovascular pharmacotherapy community and contribute to the collective endeavour to reduce the burden of cardiovascular disease. For more information about EHJ-CVP’s open access transition, please visit the Journal's homepage.
